Schizophrenia
900 results
101 - 200
Sulpiride for schizophrenia: Cochrane systematic review- Ziprasidone versus other atypical antipsychotics for schizophrenia
Family interventions in schizophrenia - Maintenance treatment with antipsychotic drugs for schizophrenia
- Zuclopenthixol dihydrochloride for schizophrenia
- Transitional discharge interventions for people with schizophrenia
- Testosterone for schizophrenia: Cochrane systematic review
- Risk assessment for aggressive behaviour in schizophrenia
- Antipsychotic medication for childhood-onset schizophrenia
- Yoga versus non‐standard care for schizophrenia
- Trifluoperazine versus placebo for schizophrenia: Cochrane systematic review
- Lamotrigine for schizophrenia: Cochrane systematic review
- New generation antipsychotics for first episode schizophrenia
- Social skills programmes for schizophrenia
- Quetiapine versus other atypical antipsychotics for schizophrenia
- Wendan decoction (Traditional Chinese medicine) for schizophrenia
- Antidepressants for people with both schizophrenia and depression
- Cognitive behavioural therapy (brief versus standard duration) for schizophrenia
- Antipsychotic drug treatment for elderly people with late‐onset schizophrenia
- Exercise therapy for schizophrenia: Cochrane systematic review
- Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms
- Video games for people with schizophrenia
- Depot pipotiazine palmitate and undecylenate for schizophrenia
- Olanzapine for schizophrenia: Cochrane systematic review
- Clozapine versus other atypical antipsychotics for schizophrenia
- Sertindole for schizophrenia
- Antioxidant treatments for schizophrenia: Cochrane systematic review
- Aripiprazole versus placebo for schizophrenia: Cochrane systematic review
- Humour‐based interventions for people with schizophrenia
- Cognitive rehabilitation for people with schizophrenia and related conditions
- Trifluoperazine for schizophrenia
- Olanzapine versus other atypical antipsychotics for schizophrenia
- Chlorpromazine dose for people with schizophrenia
- Zuclopenthixol dihydrochloride for schizophrenia
- Haloperidol dose for the acute phase of schizophrenia
- Increasing antipsychotic dose for non response in schizophrenia
- Haloperidol versus placebo for schizophrenia
- Modafinil for people with schizophrenia or related disorders
- Risperidone versus other atypical antipsychotics for schizophrenia
- Risperidone versus typical antipsychotic medication for schizophrenia
- Asenapine versus placebo for schizophrenia
- Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
- Parenting interventions for people with schizophrenia or related serious mental illness
- Depot risperidone for schizophrenia
- Family‐based interventions versus standard care for people with schizophrenia
- Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
- Interventions for smoking cessation and reduction in individuals with schizophrenia
- Cognitive behavioural therapy without medication for schizophrenia
- Atypical antipsychotics for people with both schizophrenia and depression
- Perphenazine for schizophrenia
- Chlorpromazine versus reserpine for schizophrenia: Cochrane systematic review
- Occupational therapy delivered by specialists versus non‐specialists for people with schizophrenia
- Antipsychotic medication versus placebo for people with both schizophrenia and learning disability
- Twenty‐four hour care for schizophrenia
- Risperidone versus placebo for schizophrenia
- Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses
- Selective noradrenaline reuptake inhibitors for schizophrenia
- Chlorpromazine versus placebo for schizophrenia: Cochrane systematic review
- Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness
- Electroconvulsive therapy for schizophrenia: Cochrane systematic review
- Outcome measures and needs assessment tools for schizophrenia and related disorders
- Clozapine for persistent aggressive behaviour or agitation in people with schizophrenia
- Aripiprazole for schizophrenia
- Token economy for schizophrenia: Cochrane systematic review
- Psychoeducation (brief) for people with schizophrenia
- Quetiapine for schizophrenia
- Post‐incident debriefing for people with schizophrenia after coercive measures
- Maintenance treatment with antipsychotic drugs for schizophrenia
- Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders
- Perphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia
- Clozapine dose for schizophrenia
- Day hospital versus outpatient care for people with schizophrenia
- Bromperidol decanoate (depot) for schizophrenia: Cochrane systematic review
- Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia
- Behavioural family interventions versus structural family interventions for people with schizophrenia
- Avatar Therapy for people with schizophrenia or related disorders
- Molindone for schizophrenia and severe mental illness: Cochrane systematic review
- Training to recognise the early signs of recurrence in schizophrenia
- Aripiprazole versus typical antipsychotic drugs for schizophrenia: Cochrane systematic review
- Oral paliperidone for schizophrenia: Cochrane systematic review
- Risperidone versus other atypical antipsychotic medication for schizophrenia: Cochrane systematic review
- Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
- Yoga as part of a package of care versus non‐standard care for schizophrenia
- Pimozide for schizophrenia or related psychoses
- Haloperidol dose for the acute phase of schizophrenia
- Peer support for people with schizophrenia or other serious mental illness
- Paliperidone palmitate for schizophrenia: Cochrane systematic review
- Quetiapine versus typical antipsychotic medications for schizophrenia: Cochrane systematic review
- Pimozide for schizophrenia or related psychoses: Cochrane systematic review
- Cessation of medication for people with schizophrenia already stable on chlorpromazine: Cochrane systematic review
- Pharmacological interventions for prevention of weight gain in people with schizophrenia
- Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses
- Aripiprazole versus other atypical antipsychotics for schizophrenia: Cochrane systematic review
- Electroconvulsive therapy for treatment-resistant schizophrenia
- Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia: Cochrane systematic review
No clear difference among antipsychotic agents in preventing relapse in adults with schizophrenia- Haloperidol versus first-generation antipsychotic drugs for schizophrenia
- Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia: Cochrane systematic review
- Clozapine versus typical neuroleptic medication for schizophrenia: Cochrane systematic review
- Completed suicide risk highest after attempted suicide by those with depression, schizophrenia